BRCA1 and ovarian carcinoma: Our study differs from the research conducted by Manchanda et al31 on the cost-effectiveness of population-based testing for BRCA1, BRCA2, RAD51C (OMIM 602774), RAD51D (OMIM 602954), BRIP1 (OMIM 605882), and PALB2 mutations for preventing breast and ovarian cancer in the following ways.